Undisclosed Gene Therapy

About OBiO Technology

Chinese biotech developing CRISPR-based gene and cell therapies for oncology and genetic disorders.

About Nephrogen

Nephrogen is a private, preclinical biotech leveraging its proprietary NeFIND™ platform to design next-generation gene delivery vectors for kidney and pancreatic diseases. The platform utilizes artificial intelligence and high-throughput in vivo screening to identify vectors claimed to be 10-100x more efficient, cheaper, and less immunogenic than existing options. Co-founded by a team from Stanford and Harvard, including renowned geneticist George Church, the company aims to address a major unmet need in genomic medicine delivery. Its initial target is genetic kidney diseases, with a visionary goal of curing all such conditions by 2030.

About uniQure

uniQure's mission is to reimagine the future of medicine by delivering innovative, potentially curative gene therapies for severe genetic and neurodegenerative diseases. The company's strategic foundation is its industry-leading, modular AAV5 platform, which has demonstrated a validated safety profile and holds exclusive rights for therapeutic delivery to the brain and liver. Its most advanced program, AMT-130 for Huntington's disease, represents a potential first-in-class treatment, positioning uniQure at the forefront of CNS gene therapy with a pipeline targeting high-unmet-need indications.

Therapeutic Areas